BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23196793)

  • 1. Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma.
    Rekhtman N; Tafe LJ; Chaft JE; Wang L; Arcila ME; Colanta A; Moreira AL; Zakowski MF; Travis WD; Sima CS; Kris MG; Ladanyi M
    Mod Pathol; 2013 Apr; 26(4):511-22. PubMed ID: 23196793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Landscape of Actionable Molecular Alterations in Immunomarker-Defined Large-Cell Carcinoma of the Lung.
    Chan AW; Chau SL; Tong JH; Chow C; Kwan JSH; Chung LY; Lung RW; Tong CY; Tin EK; Law PP; Law WT; Ng CSH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2019 Jul; 14(7):1213-1222. PubMed ID: 30978501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-Generation Sequencing of a Cohort of Pulmonary Large Cell Carcinomas Reclassified by World Health Organization 2015 Criteria.
    Driver BR; Portier BP; Mody DR; Deavers M; Bernicker EH; Kim MP; Teh BS; Santacruz JF; Kopas L; Munden RF; Cagle PT
    Arch Pathol Lab Med; 2016 Apr; 140(4):312-7. PubMed ID: 26430808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
    Cardarella S; Ortiz TM; Joshi VA; Butaney M; Jackman DM; Kwiatkowski DJ; Yeap BY; Jänne PA; Lindeman NI; Johnson BE
    J Thorac Oncol; 2012 Dec; 7(12):1767-1774. PubMed ID: 23154547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology.
    Rossi G; Mengoli MC; Cavazza A; Nicoli D; Barbareschi M; Cantaloni C; Papotti M; Tironi A; Graziano P; Paci M; Stefani A; Migaldi M; Sartori G; Pelosi G
    Virchows Arch; 2014 Jan; 464(1):61-8. PubMed ID: 24221342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinicopathologic features and genetic profile of the redefined large cell lung carcinoma].
    Hou LK; Zhang LP; Zhang W; Huang Y; Wu W; Dong ZW; Wu CY
    Zhonghua Bing Li Xue Za Zhi; 2017 May; 46(5):298-302. PubMed ID: 28468033
    [No Abstract]   [Full Text] [Related]  

  • 8. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical and molecular characterization of clear cell carcinoma of the lung.
    Yousem SA
    Hum Pathol; 2013 Nov; 44(11):2467-74. PubMed ID: 24029707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
    Forest F; Yvorel V; Karpathiou G; Stachowicz ML; Vergnon JM; Fournel P; Tiffet O; Trombert B; Péoc'h M
    Hum Pathol; 2016 Mar; 49():99-106. PubMed ID: 26826416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement.
    Kim HR; Shim HS; Chung JH; Lee YJ; Hong YK; Rha SY; Kim SH; Ha SJ; Kim SK; Chung KY; Soo R; Kim JH; Cho BC
    Cancer; 2012 Feb; 118(3):729-39. PubMed ID: 21720997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases.
    Terra SB; Jang JS; Bi L; Kipp BR; Jen J; Yi ES; Boland JM
    Mod Pathol; 2016 Aug; 29(8):824-31. PubMed ID: 27174587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
    Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
    Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor.
    Yeung SF; Tong JHM; Law PPW; Chung LY; Lung RWM; Tong CYK; Chow C; Chan AWH; Wan IYP; Mok TSK; To KF
    J Thorac Oncol; 2015 Sep; 10(9):1292-1300. PubMed ID: 26098749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung.
    Qiong Z; Na WY; Bo W; Zhu Z; Ling P; Bo MH; Min TY; Lei Z; Na HD; Bo Z; Fang LJ; Seng ZS
    Lung Cancer; 2015 Feb; 87(2):117-21. PubMed ID: 25488863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays.
    Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi T; Taira T; Ono A; Maniwa T; Takahashi S; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Ohde Y; Yamamoto N
    BMC Cancer; 2014 Oct; 14():786. PubMed ID: 25348872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.